Photo from Kimryn Rathmell/X
Mar 8, 2024, 19:07
Kimryn Rathmell: New drug type in the kidney cancer space and the value of rare disease research
Kimryn Rathmell, Director of
“I’m excited to see that the discovery of a drug to target HIF-2alpha, first developed for a rare disease (VHL syndrome), is now making a difference in common kidney cancers. This adds a new drug type in the kidney cancer space and highlights the value of rare disease research.”
Source: Kimryn Rathmell/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 14:08
Apr 1, 2025, 12:48
Apr 1, 2025, 12:16
Apr 1, 2025, 12:13
Apr 1, 2025, 12:07